Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
Top Cited Papers
Open Access
- 4 September 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 477 (7365), 477-481
- https://doi.org/10.1038/nature10383
Abstract
The nuclear receptor PPARγ is the target of thiazolidinedione antidiabetics including rosiglitazone and pioglitazone. These full PPARγ agonists are effective and well tolerated in most patients, but cause fluid retention and weight gain in a minority. In this proof-of-concept study, Choi et al. show the development of specific PPARγ ligands that retain antidiabetic activity through blockade of Cdk5-mediated PPARγ phosphorylation, but that are not full PPARγ agonists. In mouse models, these ligands do not cause the side effects sometimes associated with full PPARγ agonists. PPARγ is the functioning receptor for the thiazolidinedione (TZD) class of antidiabetes drugs including rosiglitazone and pioglitazone1. These drugs are full classical agonists for this nuclear receptor, but recent data have shown that many PPARγ-based drugs have a separate biochemical activity, blocking the obesity-linked phosphorylation of PPARγ by Cdk5 (ref. 2). Here we describe novel synthetic compounds that have a unique mode of binding to PPARγ, completely lack classical transcriptional agonism and block the Cdk5-mediated phosphorylation in cultured adipocytes and in insulin-resistant mice. Moreover, one such compound, SR1664, has potent antidiabetic activity while not causing the fluid retention and weight gain that are serious side effects of many of the PPARγ drugs. Unlike TZDs, SR1664 also does not interfere with bone formation in culture. These data illustrate that new classes of antidiabetes drugs can be developed by specifically targeting the Cdk5-mediated phosphorylation of PPARγ.This publication has 30 references indexed in Scilit:
- Rosiglitazone, PPARγ, and Type 2 DiabetesThe New England Journal of Medicine, 2010
- Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5Nature, 2010
- Synthesis and biological activities of novel indole derivatives as potent and selective PPARγ modulatorsBioorganic & Medicinal Chemistry Letters, 2010
- Partial Agonists Activate PPARγ Using a Helix 12 Independent MechanismStructure, 2007
- Hydrogen/deuterium‐exchange (H/D‐Ex) of PPARγ LBD in the presence of various modulatorsProtein Science, 2006
- A Unique PPARγ Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic ActivityMolecular Cell, 2001
- AdipoQ Is a Novel Adipose-specific Gene Dysregulated in ObesityOnline Journal of Public Health Informatics, 1996
- 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγCell, 1995
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994
- Severely Impaired Adipsin Expression in Genetic and Acquired ObesityScience, 1987